Posted by Michael Wonder on 25 Jan 2017
Health Canada approves Revlimid plus dexamethasone as a first-line treatment for patients newly diagnosed with multiple myeloma, not eligible for transplant
24 January 2017 - Celgene announced today that Health Canada has expanded the indication for Revlimid (lenalidomide capsules), in multiple myeloma.
Revlimid in combination with dexamethasone, is indicated for the treatment of multiple myeloma patients who are not eligible for stem cell transplant.
Nearly 60% of newly diagnosed people living with multiple myeloma are not eligible for a stem cell transplant, so the expanded indication provides a new option for this patient population, where few existed before.
